A model of care for familial hypercholesterolaemia: key role for clinical biochemistry

Gerald F Watts; David R Sullivan; Frank M van Bockxmeer; Nicola Poplawski; Ian Hamilton-Craig; Peter M Clifton; Richard C O'Brien; Peter M George; John R Burnett

A model of care for familial hypercholesterolaemia: key role for clinical biochemistry

Gerald F Watts, David R Sullivan, Frank M van Bockxmeer, Nicola Poplawski, Ian Hamilton-Craig, Peter M Clifton, Richard C O'Brien, Peter M George, John R Burnett

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma low-density lipoprotein (LDL) cholesterol concentrations and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain unrecognised and those diagnosed remain inadequately treated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory.

Original language	English
Pages (from-to)	25-31
Number of pages	7
Journal	Clinical Biochemist Reviews
Volume	33
Issue number	1
Publication status	Published - Feb 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{054cb6c45bd64813acfac282e791c913,

title = "A model of care for familial hypercholesterolaemia: key role for clinical biochemistry",

abstract = "Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma low-density lipoprotein (LDL) cholesterol concentrations and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain unrecognised and those diagnosed remain inadequately treated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory.",

keywords = "Journal Article",

author = "Watts, {Gerald F} and Sullivan, {David R} and {van Bockxmeer}, {Frank M} and Nicola Poplawski and Ian Hamilton-Craig and Clifton, {Peter M} and O'Brien, {Richard C} and George, {Peter M} and Burnett, {John R}",

year = "2012",

month = feb,

language = "English",

volume = "33",

pages = "25--31",

journal = "Clinical Biochemist Reviews",

issn = "0159-8090",

publisher = "Australasian Association of Clinical Biochemists",

number = "1",

}

TY - JOUR

T1 - A model of care for familial hypercholesterolaemia

T2 - key role for clinical biochemistry

AU - Watts, Gerald F

AU - Sullivan, David R

AU - van Bockxmeer, Frank M

AU - Poplawski, Nicola

AU - Hamilton-Craig, Ian

AU - Clifton, Peter M

AU - O'Brien, Richard C

AU - George, Peter M

AU - Burnett, John R

PY - 2012/2

Y1 - 2012/2

N2 - Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma low-density lipoprotein (LDL) cholesterol concentrations and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain unrecognised and those diagnosed remain inadequately treated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory.

AB - Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma low-density lipoprotein (LDL) cholesterol concentrations and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain unrecognised and those diagnosed remain inadequately treated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory.

KW - Journal Article

M3 - Article

C2 - 22363096

SN - 0159-8090

VL - 33

SP - 25

EP - 31

JO - Clinical Biochemist Reviews

JF - Clinical Biochemist Reviews

IS - 1

ER -

A model of care for familial hypercholesterolaemia: key role for clinical biochemistry

Abstract

UN SDGs

Fingerprint

Cite this